(Q33412410)

26 July 2017

0 references

Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials (English)

1 reference

26 July 2017

1 reference

1 reference

Zhengguang Zhang

1

1 reference

26 July 2017

Jochen Schmitt

series ordinal

2

1 reference

26 July 2017

Gottfried Wozel

series ordinal

3

1 reference

26 July 2017

Wilhelm Kirch

series ordinal

4

1 reference

26 July 2017

language of work or name

German

0 references

publication date

26 February 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

104

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

125-136

1 reference

[S3-Guidelines for the therapy of psoriasis vulgaris].

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00063-009-1024-8

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

12 December 2020

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

1 reference

12 December 2020

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

1 reference

12 December 2020

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

12 December 2020

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

12 December 2020

A systematic review of treatments for severe psoriasis

1 reference

12 December 2020

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

1 reference

12 December 2020

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis

1 reference

12 December 2020

A randomized trial of etanercept as monotherapy for psoriasis.

1 reference

12 December 2020

Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis

1 reference

12 December 2020

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

1 reference

12 December 2020

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

12 December 2020

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

12 December 2020

The economic impact of psoriasis increases with psoriasis severity.

1 reference

12 December 2020

Treatment goals in psoriasis

1 reference

12 December 2020

Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial

1 reference

12 December 2020

Etanercept and efalizumab for the treatment of psoriasis: a systematic review

1 reference

12 December 2020

Role of depression in quality of life for patients with psoriasis.

1 reference

12 December 2020

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

1 reference

12 December 2020

The risk of mortality in patients with psoriasis: results from a population-based study

1 reference

12 December 2020

Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial.

1 reference

12 December 2020

Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study.

1 reference

12 December 2020

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

1 reference

12 December 2020

Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study).

1 reference

12 December 2020

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

12 December 2020

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The search for effective and safe disease control in psoriasis

1 reference

12 December 2020

Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials

1 reference

12 December 2020

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients

1 reference

12 December 2020

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].

1 reference

12 December 2020

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

12 December 2020

Severe Psoriasis – Oral Therapy with a New Retinoid

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

Current severe psoriasis and the rule of tens.

1 reference

12 December 2020

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

1 reference

12 December 2020

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

12 December 2020

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

12 December 2020

Etanercept as monotherapy in patients with psoriasis

1 reference

12 December 2020

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

1 reference

12 December 2020

Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis

1 reference

12 December 2020

Therapy of moderate and severe psoriasis.

1 reference

12 December 2020

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

12 December 2020

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

12 December 2020

Psoriasis causes as much disability as other major medical diseases

1 reference

12 December 2020

10.1007/S00063-009-1024-8

Identifiers

DOI

1 reference

26 July 2017

1 reference